Lausanne-based Isospec Analytics has secured USD 1.9 million in Pre-Seed Funding to advance its mission of revolutionizing human health. Their breakthrough biomolecular analysis technology promises scalable identification of unknown molecules, serving pharmaceutical, agritech, and nutrition sectors.
Identifying unknown molecules in drug, nutrition, or pesticide development is crucial but often lengthy and unsuccessful. Leveraging 20 years of research, Isospec Analytics founders Ahmed Ben Faleh, Stephan Warnke, and Thomas Rizzo, fused technologies from analytical chemistry, photonics, and cryogenic materials to create a tool that rapidly generates new insights into molecular structures.
Isospec Analytics won the last stage of Venture Kick and participated in Venture Leaders Biotech in 2023.
“Venture Kick was instrumental in the development of Isospec Analytics. The funds from previous stages allowed us to acquire our first customers and further develop the technology and applications. Beyond the financial contribution, it provided us with the kick we needed to move fast via the different camps, workshops, and programs,” said Ahmed Ben Faleh, CEO of Isospec Analytics.

IsoSpec Analytics SA: Next-level molecular intelligence to empower biotechnology.
Isospec Analytics SA develops and commercializes disruptive analytical technologies to enable biomarker discovery and accelerate pharmaceutical and biotech product development. The company currently p... Read more